| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-06-23 18:07:42 |
| Primary Accession Number |
DB00727 |
| Secondary Accession Number |
|
| Name |
Nitroglycerin |
| Drug Type |
- Approved
- Investigational
- Small Molecule
|
| Description |
A volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. [PubChem] |
| Synonyms |
- Glyceryl trinitrate
- NG
- NTG
- Nitroglycerine
- TNG
- Trinitroglycerin
- nitroglycerin ointment
|
| Brand Names |
- Cellegesic
- Minitran
- Natispray
- Nitro-Dur
- Nitrocap
- Nitrolingual Pump Spray
- Nitronet
- Nitrong parenteral
- Nitrospan
- Nitrostat
- Rectogesic
- Transderm Nitro
- Tridil
|
| Brand Mixtures |
- Alchemed NP-03 (aconite + apis mellifica + arnica montana + barberry root + calendula + cantharides + charcoal activated + echinacea angustifolia + hahnemann's causticum + hypericum perforatum + nitroglycerin + urtica urens)
- Alchemed NP-04 (aesculus hippocastanum + arnica montana + barium carbonate + belladonna + celandine + cinchona officinalis + nitroglycerin + oyster shells + sepia officinalis l + strophanthus hispidus)
- Alchemed NP-21 (belladonna + cantharides + german chamomile + nitroglycerin + phosphorus + sepia officinalis l + silver nitrate + valerian + zinc)
- Aribosan B31 - liq (apis mellifica + barberry root + colchicine + convallaria majalis + nitroglycerin + poison oak + potassium iodide + quinine dihyrochloride)
- CRC-plex (arnica montana + barium chloride + calcium lactate + charcoal activated + cholesterol + convallaria majalis + epinephrine + iodine + magnesium carbonate + nitroglycerin + phosphorus + picric acid + potassium iodide + strophanthus hispidus)
- Cactus Compositum DPS (cactus grandiflorus + nitroglycerin + potassium carbonate + spigelia)
- Cere Bosan B36 - liq (belladonna + hamamelis virginiana + nitroglycerin + saffron + trillium pendulum)
- Complex 12 (aesculus hippocastanum + apis mellifica + arnica montana + barium carbonate + barium chloride + belladonna + calcium fluoride + celandine + charcoal activated + cinchona officinalis + collinsonia canadensis + conium maculatum + echinacea angustifolia + hamamelis virginiana + lycopodium clavatum + nitroglycerin + phosphorus + ruta graveolens + sepia officinalis l + sodium chloride + strophanthus hispidus + sulfur + tobacco)
- Complex 15 (belladonna + cimicifuga racemosa + cinchona officinalis + glycyrrhiza glabra + nitroglycerin + oyster shells + platinum + pulsatilla + sanguinaria canadensis + sepia officinalis l + sulfur + tiger lily + vitex agnus castus)
- Ero-bosan B20-liq (nitroglycerin + pulsatilla + sanguinaria canadensis + sepia officinalis l + vitex agnus castus)
- From time to time (belladonna + bryonia + charcoal activated + gelsemium sempervirens + lycopodium clavatum + melilot + nitroglycerin + silicon dioxide + sodium chloride + spigelia marylandica)
- Globuli no 51 (barium carbonate + cactus grandiflorus + gelsemium sempervirens + nitroglycerin)
- HPB Complex DPS (barium chloride + gold + mistletoe + nitroglycerin)
- Homeo-form MI - liquid (aluminum oxide + antimony trisulfide + cyclamen europaeum l. + lycopodium clavatum + melilot + nitroglycerin + silver nitrate)
- Homeo-form MI-tab (aluminum oxide + antimony trisulfide + cyclamen europaeum l. + lycopodium clavatum + melilot + nitroglycerin + silver nitrate)
- Homeodel 24 (belladonna + charcoal activated + gelsemium sempervirens + iris versicolor + lycopodium + nitroglycerin + spigelia)
- Homeopathic Remedy THC no.4 (aconite + arnica montana + belladonna + bryonia + cocculus indicus + gelsemium sempervirens + iris versicolor + lycopodium clavatum + nitroglycerin + potassium dichromate + pulsatilla + sanguinaria canadensis + silicon dioxide + silver nitrate + sodium chloride + spigelia marylandica + thuja occidentalis)
- Ingr-bosan b34 - liq (belladonna + cimicifuga racemosa + gelsemium sempervirens + iris versicolor + nitroglycerin + spigelia anthelmia)
- Iper-bosan b44 - liq (baryta iodata + cactus grandiflorus + gelsemium sempervirens + nitroglycerin)
- L.122 - liq orl (bryonia + cactus grandiflorus + nitroglycerin + potassium carbonate)
- L.15 DPS (aconitinum + apocynum cannabinum + arnica montana + cactus grandiflorus + nitroglycerin)
- L.73 liq (belladonna + cocculus indicus + lead acetate + mugwort + nitroglycerin + periwinkle + pulsatilla + silver nitrate + valerian)
- L2 (apis mellifica + belladonna + juglans cinerea + nitroglycerin + phytolacca decandra + pulsatilla + spongia tosta + vitex agnus castus)
- Nova - 7041 - liq (belladonna + cantharides + german chamomile + nitroglycerin + phosphorus + sepia officinalis l + silver nitrate + valerian + zinc)
- Nova 7025 - liq (aconite + apis mellifica + arnica montana + barberry root + calendula + cantharides + charcoal activated + echinacea angustifolia + hahnemann's causticum + hypericum perforatum + nitroglycerin + urtica urens)
- Nova 7028 - liq (aesculus hippocastanum + arnica montana + barium carbonate + belladonna + calcium carbonate + celandine + cinchona officinalis + nitroglycerin + sepia officinalis l + strophanthus hispidus)
- Nova 7037 - liq (belladonna + calcium carbonate + cinchona officinalis + nitroglycerin + platinum + pulsatilla + sanguinaria canadensis + sulfur + tiger lily + tin)
- Pekana - complex nr. 47 (clematis erecta + cynara scolymus + dulcamara + euphrasia officinalis + ivy + nitroglycerin + ruta graveolens + tobacco)
- R 47 dps (asafetida + coffee + musk + nitroglycerin + pulsatilla)
- R-12 dps (arnica montana + barium chloride + calcium iodide + conium maculatum + lead acetate + nitroglycerin + phosphorus + potassium iodide)
- R12 (arnica montana + barium chloride + calcium iodide + conium maculatum + lead acetate + nitroglycerin + phosphorus + potassium iodide)
- R47 (asafetida + coffee + musk + nitroglycerin + pulsatilla)
- THC complex #15 (belladonna + cinchona officinalis + gelsemium sempervirens + nitroglycerin + sodium chloride + sulfur)
- THC complex #2 (aconite + apis mellifica + arnica montana + belladonna + bryonia + cocculus indicus + ferrum phosphoricum + gelsemium sempervirens + hydrastis canadensis + iris versicolor + lycopodium clavatum + magnesium phosphate dibasic + nitroglycerin + phosphorus + potassium dichromate + potassium phosphate dibasic + pulsatilla + sanguinaria canadensis + silicon dioxide + silver nitrate + sodium chloride + spigelia marylandica + thuja occidentalis)
- THC complex #37 (aconite + bellis perennis + caulophyllum thalictroides + cimicifuga racemosa + nitroglycerin + pulsatilla + sanguinaria canadensis + strontium carbonate)
|
| Chemical IUPAC Name |
1,3-dinitrooxypropan-2-yl nitrate |
| Chemical Formula |
C3H5N3O9 |
| Chemical Structure |
 |
| CAS Registry Number |
55-63-0 |
| InChI Identifier |
InChI=1/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2 |
| InChI Key |
SNIOPGDIGTZGOP-UHFFFAOYAR |
| KEGG Drug |
D00515  |
| KEGG Compound |
C07455  |
| PubChem Compound |
4510  |
| PubChem Substance |
7847581  |
| ChEBI ID |
28787  |
| PharmGKB ID |
PA450644  |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
01926454  |
| RxList Link |
http://www.rxlist.com/cgi/generic/ntg.htm  |
| PDRhealth Link |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nit1296.shtml  |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Nitroglycerin  |
| FDA Label |
|
| Material Safety Data Sheet (MSDS) |
Not Available |
| Synthesis Reference |
Sobrero, Ann. 64, 398 (1847) |
| Average Molecular Weight |
227.0865 |
| Monoisotopic Molecular Weight |
227.0026 |
| State |
Liquid |
| Melting Point |
13.5oC |
| Experimental Water Solubility |
Slightly soluble
Source: PhysProp
|
| Predicted Water Solubility |
2.04e-01 mg/mL
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
1
Source: PhysProp
|
| Predicted LogP |
1.25
Calculated using ALOGPS
|
| Experimental LogS |
-2.22 [ADME Research, USCD] |
| Predicted LogS |
-3.05
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
Not Available |
| pKa/Isoelectric Point |
Not Available |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download  |
| SDF File |
Show | Download  |
| PDB File |
Show | Download  |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
Not Available |
| Isomeric SMILES |
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O |
| Canonical SMILES |
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O |
| Drug Category |
- Explosive Agents
- Nitrates and Nitrites
- Tocolytic Agents
- Vasodilator Agents
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For the prevention of angina |
| Pharmacology |
Nitroglycerin, an organic nitrate, is available in many forms as a vasodilator. Nitroglycerin is used in the treatement of angina pectoris and perioperative hypertension, to produce controlled hypotension during surgical procedures, to treat hypertensive emergencies, and to treat congestive heart failure associated with myocardial infarction. |
| Mechanism of Action |
Similar to other nitrites and organic nitrates, nitroglycerin is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation. |
| Absorption |
Not Available |
| Toxicity |
Increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death. |
| Protein Binding |
Not Available |
| Biotransformation |
Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation |
| Half Life |
3 minutes |
| Dosage Forms |
| Form |
Route |
| Aerosol, metered |
Sublingual |
| Disc |
Transdermal |
| Liquid |
Intravenous |
| Liquid |
Oral |
| Ointment |
Topical |
| Patch |
Transdermal |
| Solution |
Intravenous |
| Solution / drops |
Oral |
| Spray, metered |
Sublingual |
| Tablet |
Oral |
| Tablet |
Sublingual |
|
| Patient Information |
Show  |
| Contraindications |
Show  |
| Interactions |
Show  |
| Drug Interactions |
| Drug |
Interaction |
| Alteplase |
IV nitroglycerin decreases the effect of alteplase |
| Dihydroergotamine |
Possible antagonism of action |
| Dihydroergotoxine |
Possible antagonism of action |
| Ergonovine |
Possible antagonism of action |
| Ergotamine |
Possible antagonism of action |
| Methylergonovine |
Possible antagonism of action |
| Methysergide |
Possible antagonism of action |
| Sildenafil |
Possible significant hypotension with this combination |
| Tadalafil |
Possible significant hypotension with this combination |
| Vardenafil |
Possible significant hypotension with this combination |
|
| Food Interactions |
- Avoid alcohol.
- Dissolve under the tongue.
- Take on empty stomach: 1 hour before or 2 hours after meals.
|
| Pathways |
Not Available
|
| General References |
- Drugs.com

- Wikipedia

- RxList

- PDRhealth

|
| Organisms Affected |
|
| Targets |
- Aldehyde dehydrogenase, mitochondrial
- Atrial natriuretic peptide receptor A
|
|
Drug Target 1
[top]
|
| Target 1 ID |
147 |
| Target 1 Name |
Aldehyde dehydrogenase, mitochondrial |
| Target 1 Synonyms |
- ALDH class 2
- ALDH-E2
- ALDHI
- Aldehyde dehydrogenase, mitochondrial precursor
- EC 1.2.1.3
|
| Target 1 Gene Name |
ALDH2 |
| Target 1 Protein Sequence |
>Aldehyde dehydrogenase, mitochondrial precursor
MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPS
TGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLA
ALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCG
QIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPG
FGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADM
DWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGP
QVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGP
VMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQS
PFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS
|
| Target 1 Number of Residues |
525 |
| Target 1 Molecular Weight |
56382 |
| Target 1 Theoretical pI |
7.05 |
| Target 1 GO Classification |
|
Function
|
catalytic activity
oxidoreductase activity |
|
Process
|
physiological process
metabolism |
|
Component
|
| Not Available |
|
| Target 1 General Function |
Energy production and conversion |
| Target 1 Specific Function |
Not Available |
| Target 1 Pathways |
|
| Target 1 Reactions |
- an aldehyde + NAD+ + H2O = an acid + NADH + H+
|
| Target 1 Pfam Domain Function |
|
| Target 1 Signals |
|
| Target 1 Transmembrane Regions |
|
| Target 1 Essentiality |
Non-Essential |
| Target 1 GenBank ID Protein |
28606  |
| Target 1 UniProtKB/Swiss-Prot ID |
P05091  |
| Target 1 UniProtKB/Swiss-Prot Entry Name |
ALDH2_HUMAN  |
| Target 1 PDB ID |
1OF7  |
| Target 1 PDB File |
Show |
| Target 1 3D Structure |
|
| Target 1 Cellular Location |
- Mitochondrion
- mitochondrial matrix
|
| Target 1 Gene Sequence |
>1551 bp
ATGTTGCGCGCTGCCGCCGCTCGGGCCCCGCCTGGCCGCCGCCTCTTGTCAGCCGCCGCC
ACCCAGGCCGTGCCTGCCCCCAACCAGCAGCCCGAGGTCTTCTGCAACCAGATTTTCATA
AACAATGAATGGCACGATGCCGTCAGCAGGAAAACATTCCCCACCGTCAATCCGTCCACT
GGAGAGGTCATCTGTCAGGTAGCTGAAGGGGACAAGGAAGATGTGGACAAGGCACGTGAA
GGCCGCCCGGGCGCCTTCCAGCTGGGCTCACCTTGGCGCCGCATGGACGCATCACACAGC
GGCCGGCTGCTGAACCGCCTGGCCGATCTGATCGAGCGGGACCGGACCTACCTGGCGGCC
TTGGAGACCCTGGACAATGGCAAGCCCTATGTCATCTCCTACCTGGTGGATTTGGACATG
GTCCTCAAATGTCTCCGGTATTATGCCGGCTGGGCTGATAAGTACCACGGGAAAACCATC
CCCATTGACGGAGACTTCTTCAGCTACACACGCCATGAACCTGTGGGGGTGTGCGGGCAG
ATCATTCCGTGGAATTTCCCGCTCCTGATGCAAGCATGGAAGCTGGGCCCAGCCTTGGCA
ACTGGAAACGTGGTTGTGATGAAGGTAGCTGAGCAGACACCCCTCACCGCCCTCTATGTG
GCCAACCTGATCAAGGAGGCTGGCTTTCCCCCTGGTGTGGTCAACATTGTGCCTGGATTT
GGCCCCACGGCTGGGGCCGCCATTGCCTCCCATGAGGATGTGGACAAAGTGGCATTCACA
GGCTCCACTGAGATTGGCCGCGTAATCCAGGTTGCTGCTGGGAGCAGCAACCTCAAGAGA
GTGACCTTGGAGCTGGGGGGGAAGAGCCCCAACATCATCATGTCAGATGCCGATATGGAT
TGGGCCGTGGAACAGGCCCACTTCGCCCTGTTCTTCAACCAGGGCCAGTGCTGCTGTGCC
GGCTCCCGGACCTTCGTGCAGGAGGACATCTATGATGAGTTTGTGGTGCGGAGCGTTGCC
CGGGCCAAGTCTCGGGTGGTCGGGAACCCCTTTGATAGCAAGACCGAGCAGGGGCCGCAG
GTGGATGAAACTCAGTTTAAGAAGATCCTCGGCTACATCAACACGGGGAAGCAAGAGGGG
GCGAAGCTGCTGTGTGGTGGGGGCATTGCTGCTGACCGTGGTTACTTCATCCAGCCCACT
GTGTTTGGAGATGTGCAGGATGGCATGACCATCGCCAAGGAGGAGATCTTCGGGCCAGTG
ATGCAGATCCTGAAGTTCAAGACCATAGAGGAGGTTGTTGGGAGAGCCAACAATTCCACG
TACGGGCTGGCCGCAGCTGTCTTCACAAAGGATTTGGACAAGGCCAATTACCTGTCCCAG
GCCCTCCAGGCGGGCACTGTGTGGGTCAACTGCTATGATGTGTTTGGAGCCCAGTCACCC
TTTGGTGGCTACAAGATGTCGGGGAGTGGCCGGGAGTTGGGCGAGTACGGGCTGCAGGCA
TACACTGAAGTGAAAACTGTCACAGTCAAAGTGCCTCAGAAGAACTCATAA
|
| Target 1 GenBank Gene ID |
|
| Target 1 GeneCard ID |
ALDH2  |
| Target 1 GenAtlas ID |
ALDH2  |
| Target 1 HGNC ID |
HGNC:404  |
| Target 1 Chromosome Location |
12 |
| Target 1 Locus |
12q24.2 |
| Target 1 SNPs |
SNPJam Report  |
| Target 1 General References |
- Ni L, Zhou J, Hurley TD, Weiner H: Human liver mitochondrial aldehyde dehydrogenase: three-dimensional structure and the restoration of solubility and activity of chimeric forms. Protein Sci. 1999 Dec;8(12):2784-90. [PubMed
]
- Hsu LC, Bendel RE, Yoshida A: Genomic structure of the human mitochondrial aldehyde dehydrogenase gene. Genomics. 1988 Jan;2(1):57-65. [PubMed
]
- Hsu LC, Tani K, Fujiyoshi T, Kurachi K, Yoshida A: Cloning of cDNAs for human aldehyde dehydrogenases 1 and 2. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3771-5. [PubMed
]
- Braun T, Bober E, Singh S, Agarwal DP, Goedde HW: Isolation and sequence analysis of a full length cDNA clone coding for human mitochondrial aldehyde dehydrogenase. Nucleic Acids Res. 1987 Apr 10;15(7):3179. [PubMed
]
- Braun T, Bober E, Singh S, Agarwal DP, Goedde HW: Evidence for a signal peptide at the amino-terminal end of human mitochondrial aldehyde dehydrogenase. FEBS Lett. 1987 May 11;215(2):233-6. [PubMed
]
- Agarwal DP, Goedde HW: Human aldehyde dehydrogenase isozymes and alcohol sensitivity. Isozymes Curr Top Biol Med Res. 1987;16:21-48. [PubMed
]
- Hempel J, Hoog JO, Jornvall H: Mitochondrial aldehyde dehydrogenase. Homology of putative targeting sequence to that of carbamyl phosphate synthetase I revealed by correlation of cDNA and protein data. FEBS Lett. 1987 Sep 28;222(1):95-8. [PubMed
]
- Yoshida A, Ikawa M, Hsu LC, Tani K: Molecular abnormality and cDNA cloning of human aldehyde dehydrogenases. Alcohol. 1985 Jan-Feb;2(1):103-6. [PubMed
]
- Hempel J, Kaiser R, Jornvall H: Mitochondrial aldehyde dehydrogenase from human liver. Primary structure, differences in relation to the cytosolic enzyme, and functional correlations. Eur J Biochem. 1985 Nov 15;153(1):13-28. [PubMed
]
- Yoshida A, Huang IY, Ikawa M: Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A. 1984 Jan;81(1):258-61. [PubMed
]
- 8561277 Novoradovsky A, Tsai SJ, Goldfarb L, Peterson R, Long JC, Goldman D: Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Alcohol Clin Exp Res. 1995 Oct;19(5):1105-10.
|
| Target 1 Drug References |
- Zhang J, Chen Z, Cobb FR, Stamler JS: Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation. 2004 Aug 10;110(6):750-5. Epub 2004 Aug 2. [PubMed
]
- Mackenzie IS, Maki-Petaja KM, McEniery CM, Bao YP, Wallace SM, Cheriyan J, Monteith S, Brown MJ, Wilkinson IB: Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1891-5. Epub 2005 Jul 28. [PubMed
]
- Chen Z, Stamler JS: Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med. 2006 Nov;16(8):259-65. [PubMed
]
- Larson HN, Zhou J, Chen Z, Stamler JS, Weiner H, Hurley TD: Structural and functional consequences of coenzyme binding to the inactive asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487. J Biol Chem. 2007 Apr 27;282(17):12940-50. Epub 2007 Feb 27. [PubMed
]
- Chen YR, Nie SD, Shan W, Jiang DJ, Shi RZ, Zhou Z, Guo R, Zhang Z, Li YJ: Decrease in endogenous CGRP release in nitroglycerin tolerance: role of ALDH-2. Eur J Pharmacol. 2007 Sep 24;571(1):44-50. Epub 2007 Jun 5. [PubMed
]
|
|
Drug Target 2
[top]
|
| Target 2 ID |
613 |
| Target 2 Name |
Atrial natriuretic peptide receptor A |
| Target 2 Synonyms |
- ANP-A
- ANPRA
- Atrial natriuretic peptide A-type receptor
- Atrial natriuretic peptide receptor A precursor
- EC 4.6.1.2
- GC-A
- Guanylate cyclase
- NPR-A
|
| Target 2 Gene Name |
NPR1 |
| Target 2 Protein Sequence |
>Atrial natriuretic peptide receptor A precursor
MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVE
LALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVY
AAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWER
QALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGR
VIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDV
SARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLY
IQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAF
RVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGS
LSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNY
GSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVG
ACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGN
LKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAG
DVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLM
QRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLE
EKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTL
LNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFR
IRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSET
KAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG
|
| Target 2 Number of Residues |
1078 |
| Target 2 Molecular Weight |
118921 |
| Target 2 Theoretical pI |
6.61 |
| Target 2 GO Classification |
|
Function
|
protein-tyrosine kinase activity
binding
nucleotide binding
purine nucleotide binding
adenyl nucleotide binding
ATP binding
transferase activity
transferase activity, transferring phosphorus-containing groups
kinase activity
protein kinase activity
signal transducer activity
receptor activity
transmembrane receptor activity
G-protein coupled receptor activity
rhodopsin-like receptor activity
peptide receptor activity, G-protein coupled
catalytic activity
lyase activity
phosphorus-oxygen lyase activity |
|
Process
|
macromolecule metabolism
biopolymer metabolism
biopolymer modification
protein modification
protein amino acid phosphorylation
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
nucleotide metabolism
nucleotide biosynthesis
cyclic nucleotide biosynthesis
cellular process
cell communication
signal transduction
intracellular signaling cascade |
|
Component
|
cell
membrane |
|
| Target 2 General Function |
Signal transduction mechanisms |
| Target 2 Specific Function |
Receptor for atrial natriuretic peptide. Has guanylate cyclase activity on binding of ANF |
| Target 2 Pathways |
|
| Target 2 Reactions |
- GTP = 3',5'-cyclic GMP + diphosphate
|
| Target 2 Pfam Domain Function |
|
| Target 2 Signals |
|
| Target 2 Transmembrane Regions |
|
| Target 2 Essentiality |
Non-Essential |
| Target 2 GenBank ID Protein |
28230  |
| Target 2 UniProtKB/Swiss-Prot ID |
P16066  |
| Target 2 UniProtKB/Swiss-Prot Entry Name |
ANPRA_HUMAN  |
| Target 2 PDB ID |
Not Available |
| Target 2 Cellular Location |
- Membrane
- single-pass type I membrane protein
|
| Target 2 Gene Sequence |
>3186 bp
ATGCCGGGGCCCCGGCGCCCCGCTGGCTCCCGCCTGCGCCTGCTCCTGCTCCTGCTGCTG
CCGCCGCTGCTGCTGCTGCTCCGGGGCAGCCACGCGGGCAACCTGACGGTAGCCGTGGTA
CTGCCGCTGGCCAATACCTCGTACCCCTGGTCGTGGGCGCGCGTGGGACCCGCCGTGGAG
CTGGCCCTGGCCCAGGTGAAGGCGCGCCCCGACTTGCTGCCGGGCTGGACGGTCCGCACG
GTGCTGGGCAGCAGCGAAAACGCGCTGGGCGTCTGCTCCGACACCGCAGCGCCCCTGGCC
GCGGTGGACCTCAAGTGGGAGCACAACCCCGCTGTGTTCCTGGGCCCCGGCTGCGTGTAC
GCCGCCGCCCCAGTGGGGCGCTTCACCGCGCACTGGCGGGTCCCGCTGCTGACCGCCGGC
GCCCCGGCGCTGGGCTTCGGTGTCAAGGACGAGTATGCGCTGACCACCCGCGCGGGGCCC
AGCTACGCCAAGCTGGGGGACTTCGTGGCGGCGCTGCACCGACGGCTGGGCTGGGAGCGC
CAAGCGCTCATGCTCTACGCCTACCGGCCGGGTGACGAAGAGCACTGCTTCTTCCTCGTG
GAGGGGCTGTTCATGCGGGTCCGCGACCGCCTCAATATTACGGTGGACCACCTGGAGTTC
GCCGAGGACGACCTCAGCCACTACACCAGGCTGCTGCGGACCATGCCGCGCAAAGGCCGA
GTTATCTACATCTGCAGCTCCCCTGATGCCTTCAGAACCCTCATGCTCCTGGCCCTGGAA
GCTGGCTTGTGTGGGGAGGACTACGTTTTCTTCCACCTGGATATCTTTGGGCAAAGCCTG
CAAGGTGGACAGGGCCCTGCTCCCCGCAGGCCCTGGGAGAGAGGGGATGGGCAGGATGTC
AGTGCCCGCCAGGCCTTTCAGGCTGCCAAAATCATTACATATAAAGACCCAGATAATCCC
GAGTACTTGGAATTCCTGAAGCAGTTAAAACACCTGGCCTATGAGCAGTTCAACTTCACC
ATGGAGGATGGCCTGGTGAACACCATCCCAGCATCCTTCCACGACGGGCTCCTGCTCTAT
ATCCAGGCAGTGACGGAGACTCTGGCACATGGGGGAACTGTTACTGATGGGGAGAACATC
ACTCAGCGGATGTGGAACCGAAGCTTTCAAGGTGTGACAGGATACCTGAAAATTGATAGC
AGTGGCGATCGGGAAACAGACTTCTCCCTCTGGGATATGGATCCCGAGAATGGTGCCTTC
AGGGTTGTACTGAACTACAATGGGACTTCCCAAGAGCTGGTGGCTGTGTCGGGGCGCAAA
CTGAACTGGCCCCTGGGGTACCCTCCTCCTGACATCCCCAAATGTGGCTTTGACAACGAA
GACCCAGCATGCAACCAAGATCACCTTTCCACCCTGGAGGTGCTGGCTTTGGTGGGCAGC
CTCTCCTTGCTCGGCATTCTGATTGTCTCCTTCTTCATATACAGGAAGATGCAGCTGGAG
AAGGAACTGGCCTCGGAGCTGTGGCGGGTGCGCTGGGAGGACGTTGAGCCCAGTAGCCTT
GAGAGGCACCTGCGGAGTGCAGGCAGCCGGCTGACCCTGAGCGGGAGAGGCTCCAATTAC
GGCTCCCTGCTAACCACAGAGGGCCAGTTCCAAGTCTTTGCCAAGACAGCATATTATAAG
GGCAACCTCGTGGCTGTGAAACGTGTGAACCGTAAACGCATTGAGCTGACACGAAAAGTC
CTGTTTGAACTGAAGCATATGCGGGATGTGCAGAATGAACACCTGACCAGGTTTGTGGGA
GCCTGCACCGACCCCCCCAATATCTGCATCCTCACAGAGTACTGTCCCCGTGGGAGCCTG
CAGGACATTCTGGAGAATGAGAGCATCACCCTGGACTGGATGTTCCGGTACTCACTCACC
AATGACATCGTCAAGGGCATGCTGTTTCTACACAATGGGGCTATCTGTTCCCATGGGAAC
CTCAAGTCATCCAACTGCGTGGTAGATGGGCGCTTTGTGCTCAAGATCACCGACTATGGG
CTGGAGAGCTTCAGGGACCTGGACCCAGAGCAAGGACACACCGTTTATGCCAAAAAGCTG
TGGACGGCCCCTGAGCTCCTGCGAATGGCTTCACCCCCTGTGCGGGGCTCCCAGGCTGGT
GACGTATACAGCTTTGGGATCATCCTTCAGGAGATTGCCCTGAGGAGTGGGGTCTTCCAC
GTGGAAGGTTTGGACCTGAGCCCCAAAGAGATCATCGAGCGGGTGACTCGGGGTGAGCAG
CCCCCCTTCCGGCCCTCCCTGGCCCTGCAGAGTCACCTGGAGGAGTTGGGGCTGCTCATG
CAGCGGTGCTGGGCTGAGGACCCACAGGAGAGGCCACCATTCCAGCAGATCCGCCTGACG
TTGCGCAAATTTAACAGGGAGAACAGCAGCAACATCCTGGACAACCTGCTGTCCCGCATG
GAGCAGTACGCGAACAATCTGGAGGAACTGGTGGAGGAGCGGACCCAGGCATACCTGGAG
GAGAAGCGCAAGGCTGAGGCCCTGCTCTACCAGATCCTGCCTCACTCAGTGGCTGAGCAG
CTGAAGCGTGGGGAGACGGTGCAGGCCGAAGCCTTTGACAGTGTTACCATCTACTTCAGT
GACATTGTGGGTTTCACAGCGCTGTCGGCGGAGAGCACACCCATGCAGGTGGTGACCCTG
CTCAATGACCTGTACACTTGCTTTGATGCTGTCATAGACAACTTTGATGTGTACAAGGTG
GAGACAATTGGCGATGCCTACATGGTGGTGTCAGGGCTCCCTGTGCGGAACGGGCGGCTA
CACGCCTGCGAGGTAGCCCGCATGGCCCTGGCACTGCTGGATGCTGTGCGCTCCTTCCGA
ATCCGCCACCGGCCCCAGGAGCAGCTGCGCTTGCGCATTGGCATCCACACAGGACCTGTG
TGTGCTGGAGTGGTGGGACTGAAGATGCCCCGTTACTGTCTCTTTGGGGATACAGTCAAC
ACAGCCTCAAGAATGGAGTCTAATGGGGAAGCCCTGAAGATCCACTTGTCTTCTGAGACC
AAGGCTGTCCTGGAGGAGTTTGGTGGTTTCGAGCTGGAGCTTCGAGGGGATGTAGAAATG
AAGGGCAAAGGCAAGGTTCGGACCTACTGGCTCCTTGGGGAGAGGGGGAGTAGCACCCGA
GGCTGA
|
| Target 2 GenBank Gene ID |
|
| Target 2 GeneCard ID |
NPR1  |
| Target 2 GenAtlas ID |
NPR1  |
| Target 2 HGNC ID |
HGNC:7943  |
| Target 2 Chromosome Location |
1 |
| Target 2 Locus |
1q21-q22 |
| Target 2 SNPs |
SNPJam Report  |
| Target 2 General References |
- Lowe DG, Chang MS, Hellmiss R, Chen E, Singh S, Garbers DL, Goeddel DV: Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989 May;8(5):1377-84. [PubMed
]
- Pardhasaradhi K, Kutty RK, Gentleman S, Krishna G: Expression of mRNA for atrial natriuretic peptide receptor guanylate cyclase (ANPRA) in human retina. Cell Mol Neurobiol. 1994 Feb;14(1):1-7. [PubMed
]
- Takahashi Y, Nakayama T, Soma M, Izumi Y, Kanmatsuse K: Organization of the human natriuretic peptide receptor A gene. Biochem Biophys Res Commun. 1998 May 29;246(3):736-9. [PubMed
]
|
| Target 2 Drug References |
- Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [PubMed
]
|